Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02723331 · ClinicalTrials.gov registry record · Phase 2
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
A Phase 2 study of Pancreatic Cancer and Pancreatic Adenocarcinoma, sponsored by Academic Thoracic Oncology Medical Investigators Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT02723331 is a Phase 2 study of Pancreatic Cancer and Pancreatic Adenocarcinoma that has completed, run by Academic Thoracic Oncology Medical Investigators Consortium. The registered enrollment target is 48 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02723331, a Phase 2 study of Pancreatic Cancer and Pancreatic Adenocarcinoma, has completed, sponsored by Academic Thoracic Oncology Medical Investigators Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in response to neoadjuvant sequential therapy of combination nab-paclitaxel and gemcitabine followed by stereotactic body radiotherapy (SBRT).
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Nab paclitaxel
Study Locations (4)
Arizona
- Mayo Clinic Hospital - Scottsdale
- University of Arizona - Tucson
Colorado
- University of Colorado Cancer Center - Aurora
New York
- New York University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-12-30 |
| Est. Completion | 2022-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02723331
The ClinicalTrials.gov registry entry for NCT02723331 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Academic Thoracic Oncology Medical Investigators Consortium, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.
NCT02723331 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Colorado, New York.
Frequently Asked Questions
What is clinical trial NCT02723331 about?
NCT02723331 is a clinical study titled "Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates". The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in response to neoadjuvant sequential therapy of combination nab-paclitaxel...
What is the current status of trial NCT02723331?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2016-12-30. Estimated completion is 2022-12-28.
What conditions does trial NCT02723331 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma.
What interventions are being tested in trial NCT02723331?
The interventions under investigation include: Gemcitabine (DRUG), Nab paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02723331?
This trial is sponsored by Academic Thoracic Oncology Medical Investigators Consortium, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02723331 being conducted?
This trial has 4 study locations across Arizona, Colorado, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.